-
">
1.发明申请Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" 审中-公开逆转黑色素瘤抑制活性的免疫抑制作用的方法“mia”公开(公告)号：US20060252716A1
公开(公告)日：2006-11-09
申请号：US10220265
申请日：2001-03-10
申请人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Rainer Apfel , Wolfgang Brysch , Piotr Jachimczak , Ulrich Bogdahn
发明人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Rainer Apfel , Wolfgang Brysch , Piotr Jachimczak , Ulrich Bogdahn
IPC分类号： A61K48/00
CPC分类号： A61K38/1709 , A61K31/70 , A61K31/7088 , A61K39/395
摘要： A method for stimulating immune cells and/or the immune system, and/or reducing invasion and/or metastasis of tumor cells by inhibiting expression and/or functional activity of “Melanoma Inhibitory Activity” MIA.
摘要翻译： 通过抑制“黑素瘤抑制活性”MIA的表达和/或功能活性来刺激免疫细胞和/或免疫系统和/或减少肿瘤细胞的侵袭和/或转移的方法。
-
2.发明授权Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β) 失效用于治疗转化生长因子的免疫抑制作用的反义寡核苷酸 （TGF-＆bgr）公开(公告)号：US07667027B2
公开(公告)日：2010-02-23
申请号：US11647586
申请日：2006-12-29
申请人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
发明人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
IPC分类号： C07H21/04
CPC分类号： C12N15/1136 , C12N2310/315
摘要： Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-β (TGF-β) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
摘要翻译： 与编码转化生长因子的基因的区域杂交的反义寡核苷酸或其有效的衍生物; （TGF-β），其包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 1-56和137，或包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 57〜136个具有DNA或RNA型结构的核酸。
-
3.发明申请Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta) 失效用于治疗转化生长因子-β（TGF-β）的免疫抑制作用的反义寡核苷酸公开(公告)号：US20080214483A1
公开(公告)日：2008-09-04
申请号：US11647586
申请日：2006-12-29
申请人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
发明人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
IPC分类号： A61K31/711 , C07H21/04
CPC分类号： C12N15/1136 , C12N2310/315
摘要： Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-β (TGF-β) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
摘要翻译： 与编码转化生长因子-β（TGF-β）的基因的区域杂交的反义寡核苷酸或其有效衍生物包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 1-56和137，或包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 57〜136个具有DNA或RNA型结构的核酸。
-
4.发明授权Antisense-oligonucleotides for transforming growth factor-&bgr; (TGF-&bgr;) 失效用于转化生长因子-β（TGF-β）的反义寡核苷酸公开(公告)号：US06455689B1
公开(公告)日：2002-09-24
申请号：US08535249
申请日：1995-10-30
申请人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
发明人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
IPC分类号： C07H2102
CPC分类号： C12N15/1136 , C12N2310/315
摘要： Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-&bgr; (TGF-&bgr;) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
摘要翻译： 与编码转化生长因子-β（TGF-β）的基因的区域杂交的反义寡核苷酸或其有效衍生物包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 1-56和137，或包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 57〜136个具有DNA或RNA型结构的核酸。
-
5.发明授权Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role 失效用于预防和治疗其中c-erbB表达起作用的病症的反义核酸公开(公告)号：US06365345B1
公开(公告)日：2002-04-02
申请号：US08666341
申请日：1996-08-15
申请人： Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Georg-Ferdinand Schlingensiepen
发明人： Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Georg-Ferdinand Schlingensiepen
IPC分类号： C07H2104
CPC分类号： A61K31/70 , C12N15/1138
摘要： The present invention is related to an antisense-nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the p185erbB-2 receptor (also termed c-erbB-2, HER2 or neu), a pharmaceutical composition, comprising an antisense nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the c-erbB-2 receptor as well as the use of said antisense nucleic acids and derivatives thereof for the manufacturing of a pharmaceutical composition for the treatment of neoplasms and/or immune diseases and/or diseases involving pathological angiogenesis.
摘要翻译： 本发明涉及与编码p185erbB-2受体（也称为c-erbB-2，HER2或neu）的信使RNA（mRNA）或DNA的区域杂交的反义核酸或其有效衍生物， 一种药物组合物，其包含与编码c-erbB-2受体的信使RNA（mRNA）或DNA的区域杂交的反义核酸或其有效衍生物，以及将所述反义核酸及其衍生物用于 用于治疗涉及病理性血管发生的肿瘤和/或免疫疾病和/或疾病的药物组合物的制造。
-
公开(公告)号：US08629117B2
公开(公告)日：2014-01-14
申请号：US11898080
申请日：2007-09-07
CPC分类号： A61K45/06 , A61K2039/505
摘要： Medicament comprising a combination of at least one inhibitor of the effect of a substance negatively effecting an immune response, the substance selected from the group consisting of TGF-β and its receptors, VEGF and its receptors, interleukin 10 (IL-10) and its receptors, PGE2 and its receptors, wherein the inhibitor has a molecular weight of less than 100 kDa and at least one stimulator positively effecting an immune response.
摘要翻译： 药物，其包含至少一种负面影响免疫应答的物质的作用抑制剂的组合，所述物质选自TGF-β及其受体，VEGF及其受体，白介素10（IL-10）及其受体 受体，PGE2及其受体，其中所述抑制剂具有小于100kDa的分子量和至少一种正向影响免疫应答的刺激物。
-
7.发明授权Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms 失效包含用于预防和/或治疗神经元损伤，变性和细胞死亡以及用于治疗赘生物的反义核酸的药物组合物公开(公告)号：US07326783B2
公开(公告)日：2008-02-05
申请号：US08591486
申请日：1994-07-06
申请人： Georg-F Schlingensiepen , Reimar Schlingensiepen , Karl-Hermann Schlingensiepen , Wolfgang Brysch
发明人： Georg-F Schlingensiepen , Reimar Schlingensiepen , Karl-Hermann Schlingensiepen , Wolfgang Brysch
CPC分类号： C12N15/1135 , C12N2310/315
摘要： A pharmaceutical composition comprising an effective amount of a compound which is capable from preventing and treating neuronal injury, degeneration, cell death and/or neoplasms in which expression of c-jun, c-fos or jun-B plays a causal role which compound being an antisense nucleic acid or effective derivative thereof, said antisense nucleic acid hybridizing with an area of the messenger RNA (mRNA) and/or DNA encoding c-jun, c-fos or jun-B.
摘要翻译： 一种药物组合物，其包含有效量的能够预防和治疗其中c-jun，c-fos或jun-B的表达具有因果作用的神经元损伤，变性，细胞死亡和/或赘生物的化合物，该化合物为 反义核酸或其有效衍生物，所述反义核酸与编码c-jun，c-fos或jun-B的信使RNA（mRNA）和/或DNA的区域杂交。
-
公开(公告)号：US20080124301A1
公开(公告)日：2008-05-29
申请号：US11898080
申请日：2007-09-07
IPC分类号： A61K38/20 , A61K31/7052 , A61K35/76 , A61K39/12 , A61K39/00 , A61K35/12 , C07H21/00 , A61P37/04
CPC分类号： A61K45/06 , A61K2039/505
摘要： Medicament comprising a combination of at least one inhibitor of the effect of a substance negatively effecting an immune response, the substance selected from the group consisting of TGF-β and its receptors, VEGF and its receptors, interleukin 10 (IL-10) and its receptors, PGE2 and its receptors, wherein the inhibitor has a molecular weight of less than 100 kDa and at least one stimulator positively effecting an immune response.
摘要翻译： 药物，其包含至少一种负面影响免疫应答的物质的作用抑制剂的组合，所述物质选自TGF-β及其受体，VEGF及其受体，白介素10（IL-10）及其受体 受体，PGE 2和其受体，其中抑制剂具有小于100kDa的分子量和至少一种积极影响免疫应答的刺激物。
-
9.发明授权Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene 失效包含基因的抑制剂或抑制子和与该基因的表达产物结合的分子的混合物公开(公告)号：US08703729B2
公开(公告)日：2014-04-22
申请号：US12382415
申请日：2009-03-16
IPC分类号： C12N15/113 , C07H21/04
CPC分类号： C12N15/1136 , A61K38/00 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/22 , C07K16/32 , C07K2317/73 , C12N15/1138 , C12N2310/315 , A61K2300/00
摘要： A mixture comprising at least one inhibitor or suppressor of the expression of a gene and at least one molecule binding to an expression product of said gene.
摘要翻译： 包含至少一种表达基因的抑制剂或抑制剂和至少一种与所述基因的表达产物结合的分子的混合物。
-
10.发明申请Use Of Low Doses Of Oligonucleotides Antisense To TGF-Beta, VEGF, Interleukin-10, C-Jun, C-Fos Or Prostaglandin E2 Genes In The Treatment Of Tumors 有权使用低剂量的寡核苷酸对TGF-β，VEGF，白介素-10，C-Jun，C-Fos或前列腺素E2基因在肿瘤治疗中的反义公开(公告)号：US20090306176A1
公开(公告)日：2009-12-10
申请号：US11792041
申请日：2006-05-04
IPC分类号： A61K31/7105 , A61K31/7088
CPC分类号： C12N15/1136 , C12N15/111 , C12N15/113 , C12N15/1135 , C12N2310/11 , C12N2320/30
摘要： This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM.
摘要翻译： 本发明涉及使用长度为约8至约30个核苷酸构建单元的至少一种寡核苷酸以制备用于预防和/或治疗由TGF-β2，TGF调节的疾病的药物制剂 β1，TGF-β3，VEGF，白细胞介素-10，c-jun，c-fos和/或前列腺素E2，其中所述寡核苷酸与TGF-β2，TGF-β1，TGF- β3，VEGF，白细胞介素-10，c-jun，c-fos和/或前列腺素E2基因，并且其中所述制剂包含浓度为约1微摩尔至约25微摩尔的所述寡核苷酸。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.024 秒)
